An observational study in Multiple Sclerosis, Relapsing-Remitting, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Sheffield Teaching Hospitals NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · United Kingdom.
Among the 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom, this one is the only one that started in 2023, is one of 9 observational ones, and was the 57th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →3 of the 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 120 across 157 observational studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 410 across the 51 interventional studies, 200 across the 9 observational. Of the 50 that completed or were terminated, 35 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 60 have an industry lead sponsor. The 10 most frequent:
Sheffield Teaching Hospitals NHS Foundation Trust is the lead sponsor of 214 studies on the registry; 27 are open to participants now.
Sheffield Teaching Hospitals NHS Foundation Trust has 1 study filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
4 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201638Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT03535298The Cleveland ClinicDetermining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | 2027-07-30 |
| NCT03783416Queen Mary University of LondonSIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | 2027-07-31 |
| NCT06195800Sheffield Teaching Hospitals NHS Foundation TrustIdentifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. Over the last 20 years more than 1800 patients with MS have been treated in Europe with high levels of success. It may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. There is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. Whilst aHSCT is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment.
Unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs.
This study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing aHSCT and compare it to those receiving disease modifying treatment. This study will therefore further the understanding of biomarkers of aHSCT to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.
Outpatients who are attending the Sheffield (UK) transplant clinic for neurological disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Inability to provide .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with aggressive disease treated with autologous haematopoetic stem cell transplantation.
Patients with aggressive disease treated with high efficacy disease modifying treatment
Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment.
Phenotype profiling of stem cells, cells in blood and CSF using multi-parameter flow cytometry. Profile the gut microbiome using 16S rRNA sequencing and flow cytometric analysis.
Time frame: 24 months
Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment.
Profiling of T cell receptor and B cell receptor repertoire diversity and clonality
Time frame: 24 months
Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips.
Assess immune response in treated patients post vaccination.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS)
EDSS to be observed longitudinally following treatment.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA)
LCLA to be observed longitudinally following treatment.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC)
MSFC to be observed longitudinally following treatment.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36)
SF-36 to be observed longitudinally following treatment.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to symbol digit modality test (SDMT)
SDMT to be observed longitudinally following treatment.
Time frame: 24 months
Evaluate immunological disease response and the duration of response to aHSCT according to Karnofsky performance status
Karnofsky performance status to be observed longitudinally following treatment.
Time frame: 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Nov 2027, 51 months after the start.
Of 42 non-industry observational studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 56. This study's planned 51 months is above that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 22 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2026 → Nov 2027 and completion Aug 2026 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →
Sheffield Teaching Hospitals NHS Foundation Trust →